We have a high risk of being misunderstood by others or even confusing ourselves when using English words for medical conditions, especially when they suggest or imply the aetiology of a condition or event. Consider the terms primary and secondary. The Oxford English Dictionary (the Bible to most of us born pre-Wikipedia) defines primary as: of chief importance, principal, main, chief, key, principal, foremost predominant, overriding, major, ruling, dominant, master, supreme, cardinal, pre-eminent, ultimate. A parallel definition is: earliest in time or order, initial, original, beginning, first. Secondary, in contrast, is defined as: coming after, less important than, resulting from someone or something else that is primary, subordinate, lesser, minor, peripheral, tangential, marginal, ancillary, subsidiary, subservient, non-essential, unimportant or less important. But how are these terms used in medicine? Confusingly at best, incorrectly at worst.
Let us consider the use of these terms in the setting of a haematopoietic cell transplant. Persons failing to recover normal bone marrow function after a transplant are sometimes referred to as having primary graft-failure whereas persons with initial recovery of bone marrow function followed by deterioration or loss of bone marrow function are referred to as having secondary graftfailure. But what do these labels really mean? Is primary graftfailure the result of a non-functioning or poorly functioning graft (for example, the relevant haematopoietic cells may have been killed or incapacitated during the freezing or thawing processes), an abnormal bone marrow microenvironment, immune-mediated graft-rejection, exposure to drugs harmful to the graft, a combination of these or something(s) else? It is simplistic to suggest that only one mechanism might operate in a transplant recipient or that all transplant recipients with primary graft-failure have the same mechanism or combination of mechanisms. For example, in a study of persons with aplastic anaemia receiving a transplant from a genetically identical twin, about one-half of subjects recovered normal bone marrow function after the twin haematopoietic cells were infused. 1 These persons were presumed to have aplastic anaemia from abnormal or absent haematopoietic stem or precursor cells, but a modern interpretation (which I regard as unlikely, but then again who am I to say?) is that their bone marrow microenvironment was defective and restored by unspecified cells in the graft other than haematopoietic stem or progenitor cells such as mesenchymal stromal cells. (I am reminded of the observation that pigs do not fly. But is it because they cannot fly or because they can but do not wish to?) However, the other one-half of recipients did not recover after the twin graft but another one-half of one-half recovered when a second bone marrow infusion was preceded by high-dose cyclophosphamide and were assumed to have immune-mediated aplastic anaemia.
Interestingly, none of the recipients appeared to have an irreversible bone marrow microenvironment abnormality. These observations raise concerns regarding how we should interpret data from persons with so-called primary graft-failure.
Secondary graft-failure is an even bigger mess. Secondary to what? Or does secondary simply imply an event that occurs later, after initial bone marrow recovery? Here we have even more potential explanations including more bone marrow toxic drugs, infections (bacterial and viral, especially CMV and parvoviruses), GvHD and so on. It seems even more simplistic to think that only one mechanism operates or that the same mechanism(s) operate in all persons with secondary graft-failure.
Into this fray jump Kong et al.
2 from Huang's group at People's Hospital in Beijing. First, the reader should know that the authors are my colleagues and that I reviewed their typescript before and after it was submitted. One thing I suggested was they use the term early and late rather than primary and secondary. They initially resisted but, interestingly, caved in when I suggested the same change as a reviewer. I suspect this was not because they ever thought my suggestion correct but because they feared their typescript might be rejected. (Humans are quite adaptable.) This change, although more accurate, hardly sheds light on this complex issue but at least we eliminate the ambiguity of primary and secondary, a minor victory. They also use the term graft function rather than graft-failure, but this difference seems less important.
The authors previously reported abnormalities of bone marrow endosteal cells, perivascular cells and endothelial cells in persons with late poor graft function. 3 In this small, nested, case-control study they now report similar abnormalities in persons with early poor graft function. The question is whether these data are credible and whether they help us understand graft-failure after haematopoietic cell transplants. The studies are carefully conducted and the investigators reliable. Surely some of the abnormalities they describe are associated with occasional cases of early and late poor graft function. However, it seems rather unlikely that there would be a single aetiology of poor graft function in such a diverse clinical setting. It is also a bit curious as to why some of the subjects with late graft-failure could have seemingly normal bone marrow function for prolonged intervals if they had a fundamental abnormality of the bone marrow microenvironment unless this is an acquired defect. However, associations are not cause and effect and we are always left with the question whether these abnormalities cause or result from defective bone marrow function. En guarde for the logical fallacy of post hoc ergo propter hoc.
Regardless of how convinced you are by these data, the study is interesting and deserves critical discussion. The author's suggestion that infusing mesenchymal stem cells (I think they mean mesenchymal stromal cells) may reverse poor graft function is interesting but needs to be tested in randomized trials. Do not bet the farm on a successful outcome in such a heterogeneous clinical setting. As the authors indicate, several other risk factors for poor graft function are reported. For example, in a recent analysis of primary graft-failure in more than 23 000 allotransplant recipients Olsson et al. reported diverse variables such as type of graft (blood versus bone marrow cells), recipient age, donor/recipient gender match, disease, disease state, spleen state and splenectomy (in myeloproliferative and myelodysplastic syndromes), conditioning regimen, use of frozen cells, use of haematopoietic growth factors, type of GvHD prevention and transplant year to be significantly associated with primary graft-failure in multivariate analyses. 4 If this list seems too long, recall that graft-failure is complex and often multi-factorial.
Back to the Kong et al. 2 typescript. It seems rather unlikely that the impact of all of these confounded variables on bone marrow function would end up in a common histological pattern of bone marrow failure in a cohort of 10 subjects. Albert Einstein said: 'Everything should be made as simple as possible, but no simpler'. Their finding may be an example of making a complex issue too simple unless we envision the abnormalities they describe as the effect rather than the cause of early bone marrow failure.
Data in these two reports also give us perspective on the problem of early graft-failure: an incidence of about 5%. Hardly a public health problem, although the incidence of early graftfailure in recipients of HLA-haplotype-matched transplant such as those studied by Kong et al.
2 may be slightly higher. A few suggestions follow: first, I suggest that we adopt the terms early and late rather than primary and secondary when the bone marrow heads south. This change sheds no new light on this issue, but at least we have accurate temporal descriptors. Second, I suggest that we adopt the term graft-failure rather than poor graft function as we do not know how well the haematopoietic cells are functioning versus quantitative abnormalities in normally functioning cells. Our readout of graft-failure is, of course, arbitrary and might reasonably be numbers of short-lived cells such as granulocytes and platelets in the blood. When these are below a clinically safe concentration, say granulocytes o 1 10E+9/L or platelets o 50 10E+9 platelets, we can say someone has graftfailure provided other explanations are excluded such as disseminated intravascular coagulation, drug toxicities and so on.
The reader may wonder why, with so many caveats to the Kong et al. 2 typescript, I recommended it for publication in Bone Marrow Transplantation. Simply because I am so often wrong in my thinking!
